HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT.
RETACRIT® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use
Initial U.S. Approval: 2018
RETACRIT (epoetin alfa-epbx) is biosimilar1 to EPOGEN/PROCRIT (epoetin alfa)
WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.